Focus: Cipla is a Mumbai-headquartered generics and API manufacturer specializing in infectious diseases, oncology, and respiratory therapeutics with a global portfolio of post-LOE branded generics. The company derives 33% of revenue from a single product (Darunavir), indicating a concentrated but established revenue base.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cipla to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Accounts for 33% of company revenue but faces inevitable generic competition erosion post-loss-of-exclusivity.
Help build intelligence for Cipla
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cipla's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue contributor in a specialty indication but post-exclusivity decline trajectory.
Multiple formulations across oncology indication; mature product with predictable but declining revenue stream.
Antiretroviral generic in crowded market with limited differentiation or growth potential.
Niche antibiotic indication with stable but limited market size.
40 discontinued, 39 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub
+84 more products